Chimerix
Chimerix develops innovative medicines for cancer and other serious diseases, with a focus on oncology and imipridones. Their lead product, ONC201, is in Phase 3 trials for gliomas and has received multiple FDA designations.
Services
Chimerix is dedicated to developing innovative medicines for cancer and other serious diseases. The company focuses on oncology, with a specialization in imipridones. Chimerix offers advanced clinical development and regulatory experience, aiming to improve and extend the lives of patients facing deadly diseases. They provide Expanded Access and Managed Access Programs for their oncological treatments in regions including the US, UK, Spain, Germany, and Australia.
Products
Chimerix’s product pipeline includes several promising oncology drugs. ONC201 (dordaviprone) is in a Phase 3 ACTION study for gliomas and has received multiple designations from the FDA, including Fast Track, Rare Pediatric Disease, and Orphan Drug for treating glioblastoma and malignant glioma. ONC206 is in Phase 1 clinical trials for central nervous system tumors. ONC212 is in IND-enabling studies targeting pancreatic cancer and leukemia. Additionally, CMX521 is in preclinical development for SARS-CoV-2 (COVID-19).
Clinical Trials and Studies
Chimerix is actively engaged in multiple clinical trials for its oncology-focused therapeutics. ONC201 is currently in a Phase 3 ACTION study for gliomas and showed promise in preclinical studies for advanced cancers, including neuroendocrine tumors. ONC206 is undergoing Phase 1 trials targeting central nervous system tumors. ONC212 is in IND-enabling studies aimed at tackling pancreatic cancer and leukemia. The company strives to develop medicines with the potential to make significant impacts on patient health and longevity.
Collaborations and Partnerships
Chimerix is seeking collaborations in precision oncology and neuro-oncology programs. The company’s efforts extend to both solid tumors and central nervous system tumors. By partnering with other entities, Chimerix aims to advance its oncology research and bring innovative therapies to market. The company’s strong culture of execution and extensive clinical development experience make it a valuable collaborator in the medical research community.
Headquarters and Locations
Chimerix is headquartered in Durham, North Carolina. The company also maintains an office in Dublin, Ireland, supporting its operational and strategic initiatives. These locations enable Chimerix to manage its clinical, regulatory, and development activities efficiently, fostering a collaborative environment to achieve its mission in medicine development.